Objective: To describe the first 3 years of experience of having an inpatient "cardiogenetics" program which involves medical geneticist assessment of infants with major congenital heart disease (CHD) requiring surgical intervention in the first year of life. Patients: Patients less than a year of age admitted to Children's Hospital of Wisconsin's Herma Heart Institute for surgical intervention for CHD seen by the cardiogenetics program. Patients with major trisomies (13, 18, and 21) were excluded. Outcome Measures: Utilization and yield of genetic testing, and diagnostic rate were assessed as outcome measures and compared to a baseline time period and a genetic testing protocol time period. Results: There were 201 infants with CHD evaluated by the cardiogenetics program over 3 years. A total of patients 46 patients of the 196 who underwent genetic testing had multiple tests completed. This is a significant decrease from the baseline (247/329, P < .0001) and from the genetic testing protocol (29/81, P < .0387) time periods. The diagnostic rate was 33% which is significantly increased compared to the baseline rate of 15% (80/524, P < .0001) and trends toward a significant increase during the testing protocol rate (25/113, P = .0520). The number of dual diagnosis increased to 9 of 201 compared to the baseline (2/524) and the genetic testing protocol (1/113) time periods. The rate of incidental diagnoses altering care increased to 6 of 201 from the baseline (1/524) and the genetic testing protocol (1/113) time periods. Conclusion: An inpatient cardiogenetics program significantly increases the diagnostic rate, the detection of complex phenotypes with dual diagnoses, the identification of incidental genetic diagnoses associated with changes in care, and significantly decreases the likelihood of multiple tests being completed on an individual patient. Increased medical geneticist involvement in programs that care for infants with CHD should be encouraged to improve patient care and genetic testing utilization. K E Y W O R D S cardiovascular genetics, congenital heart disease, genetic testing | 833 GEDDES Et al.
| INTRODUC TI ON
Congenital heart disease (CHD) is the most common birth defect and a significant cause of neonatal morbidity and mortality. 1 Survival rates for even the most severe forms of critical CHD have improved significantly in the modern era, shifting research into focusing on the ability to improve or modify the morbidities associated with surviving critical CHD. 2 One of the many considerations for a patient with CHD is the etiology of their malformation and genetic assessment of CHD is becoming more emphasized in the care of these patients. 3, 4 Participation of a medical geneticist in care for individuals with CHD has been repeatedly recommended and shown to be beneficial for patients with CHD of all ages in both inpatient and outpatient settings for improvement of patient care and improved resource utilization. [5] [6] [7] [8] [9] It is well established that the presence of a genetic syndrome greatly affects outcomes and that genetic syndromes are often diagnosed later during follow up. 8, 10, 11 Studies specific to medical geneticist participation in the care of infants in the cardiac critical care unit are limited, but establish an anticipated diagnostic rate of 25% across all patients. 9 Our institution aimed to improve care for infants with critical CHD by implementing a cardiovascular genetics or "cardiogenetics" program which increased involvement of medical genetics in the neonatal period to identify genetic conditions more consistently.
This article reviews the data from the first 3 years of this program and by comparison to previously assessed baseline data quantifies the impact of the program on patients with CHD.
| ME THODS
This project was reviewed by the Children's Hospital of Wisconsin institutional review board and deemed exempt as this information is primarily utilized for internal program quality improvement. The data from this project spans from the start of the cardiovascular genetics program on the first of July 2015 to the end of June 2018.
| Program structure
The structure of the inpatient cardiogenetics program has evolved over time. At its initiation in July 2015, the program was based on request for consult by members of the primary team for evaluation by a single medical geneticist (GCG) to evaluate infants with CHD. Patients with isolated atrial septal defects requiring surgical intervention before a year of age did not undergo routine assessment. Due to existing resources specific to patients with trisomy 21, they were excluded from the program in the absence of a specific request for program involvement. In August 2015, it was determined that the service would be more helpful if the medical geneticist was present during the weekly sign out of patients in the cardiac intensive care unit and on the cardiology service as well as the weekly review of upcoming surgical patients. Since that time the medical geneticist (GCG) has regularly attended these meetings. In January 2016, after review for the first 6 months of program data, it was established practice within the Herma Heart Institute that all new patients with CHD admitted to the hospital would be eligible for consultation by the cardiogenetics team. In April 2017, a single genetic counselor (ES) began to support result tracking, result disclosure, and parental counseling. All patients in the program underwent full medical genetics assessment by a single geneticist (GCG). As this data are part of an IRB exempt quality improvement project, we are unable to get the specific data on all patients to determine exactly what percentage of eligible patients underwent assessment. To estimate what number of target patients underwent consults, we took total volume of CHD surgeries in patients less than a year of age and reduced them by 12% to account for our longstanding rate of trisomy 21 in this population (109/891) that is previously published. 12 However, this number included surgical interventions for atrial septal defects before a year of age and multiple procedures performed on the same patient and is thus an overestimate of how many patients would have been eligible for cardiogenetics consultation.
| Inclusion criteria
There were a total of 281 cardiovascular genetics consults over the first 3 years. Of these, there were 207 consults in patients with CHD less than a year of age. After excluding patients with major trisomies (13(0), 18(3), and 21 (3)), there were 201 infants with CHD remaining in this cohort. Patients with trisomy 21 were excluded due to existing resources to support patients with this diagnosis. Patients with trisomies 13 and 18 were excluded as cardiac intervention in these patients is still controversial. Data are prospectively tracked and retrospectively analyzed as part of quality improvement for the cardiogenetics program.
| Testing and diagnostic rate
All known genetic testing, including prenatal testing and testing completed at outside institutions, is included in our totals. All known genetic diagnoses were recorded. Genetic diagnoses not related to the patients' cardiac phenotype were recorded as incidental and did not count toward the diagnostic rate. Copy number variants reported as variants of uncertain significance were not included in the diagnostic rate but were included in the abnormal microarray result rate.
Cardiac phenotype was recorded by National Birth Defects Prevention
Study's classification criteria into their eight "level three" categories: anomalous pulmonary venous return, atrioventricular septal defects, complex, conotruncal, heterotaxy, left ventricular outflow tract obstructions, right ventricular outflow tract obstructions, and septal. 13 Lesions excluded by this system are classified as other. Comparison data for genetic testing patterns and diagnostic rate are based on data from a previously published cohort from our institution. 12 Data on two time periods were taken from this cohort, which was matched to the cardiogenetic program population to only include infants without major trisomies. The first time period is "Baseline" which refers to data from January 2010 to December 2013 prior to any interventions where patients may or may not have had evaluation by a geneticist and may or may not have had genetic testing. The second is "Testing Protocol" which refers to data from July 2014 to June 2015, or the year immediately preceding the program where a microarray-based genetic testing protocol was in place for infants with CHD, but assessment by a medical geneticist was not routine. Further details regarding these cohorts have been previously published. 12
| Data analysis
Descriptive statistics were utilized for cohort characteristics, the proportion of specific cardiac lesions represented within the sample, the frequency of abnormal genetic test results in proportion to tests completed, and presence of genetic diagnosis. As appropriate,
Fisher's exact test analyses compared the frequency of abnormal genetic test results between cohorts. A significance level of P < .05 was used to evaluate all comparisons.
| RE SULTS

| Cohort characteristics
Fifty-six percent of the cohort were male. Seventy-four percent of the cohort were diagnosed with congenital heart disease prenatally. A summary of all cohorts used in this study (Baseline, Testing Protocol, and Cardiogenetics Program) is illustrated in Table 1 . The most common type of lesion in our cohort was conotruncal (n = 70) followed by left ventricular outflow tract obstructive lesions (n = 63).
A breakdown of lesions observed in this cohort are demonstrated in Table 2 .
| Consult characteristics
The average age at consult was 24 days, with a median of 3 days, and a range of 0-278 days. The most common consulting service was the neonatal intensive care unit (37%) and cardiology (25%). There was an average of 5-6 consults per month and consult volume was relatively stable over time as demonstrated in Figure 1 
| Genetic testing
The number of genetic tests completed both prenatally and postnatally is summarized in Table 3 .
| Prenatal testing
Twenty-two (15%) of the 150 patients with a prenatal diagnosis of CHD underwent prenatal genetic testing. Two patients underwent prenatal karyotype alone, eight patients underwent prenatal microarray alone, eleven patients underwent prenatal karyotype and microarray, and one patient underwent prenatal karyotype, 22q11.2 deletion testing, and microarray.
| Karyotype
Half of the 28 karyotypes were completed prenatally. Of the remaining 14 postnatal karyotypes, 7 were sent by outside providers prior to genetics involvement in the case. Of the seven karyotypes recommended based on the genetics evaluation, three were sent based on clinical characteristics of the infant and four were sent due to a family history of multiple miscarriages. Both abnormal postnatal karyotypes were karyotypes recommended based on the genetics evaluation.
| Microarray
Microarray alone was the most common testing strategy, completed in 144 patients. Chromosomal microarray had a yield of 25%. Six variants of uncertain significance were identified which are not included in the diagnostic rate. 
TA B L E 1 Cohort characteristics
| Exome sequencing
Exome sequencing was only considered abnormal if it was conclusively diagnostic. Sixteen patients had exome sequencing completed.
The yield was extremely high in this population, with 11 (69%) of these tests being conclusively diagnostic. This likely reflects selection bias and careful resource curation by the medical geneticist. multiple tests from baseline (247/329, P < .0001) and from the testing protocol (29/81, P < .0387) periods.
| Other genetic testing
| Multiple genetic tests
| Diagnostic rate
Sixty-six of 201 (33%) patients had a genetic diagnosis related to their congenital heart disease. The most common diagnosis was 22q11.2 deletion syndrome in 15 patients (7%). This is a significant increase in diagnostic rate from baseline (80/524, P < .0001) time period and trends toward a significant increase from the testing protocol (25/113, P = .0520) time period. Table 2 demonstrates the spread of diagnoses by cardiac lesion type. It is interesting to note the low number of diagnoses in the RVOTO compared to other groups with a substantial number of patients. and complete identification of these factors has significant potential to help patients. 11 This data are compelling that medical geneticist evaluation provides significant benefit to infants with CHD. It also should be noted that despite the proven utility of these consultations, unfortunately access to medical geneticists is limited. 3 Another interesting finding in our data are that only 15% of our patients who had a prenatal diagnosis of CHD undergo prenatal genetic testing. It is unclear as to why this is, anecdotally it seems that families perceive prenatal genetic testing to be only for the purposes of decision making regarding termination vs medical care for the infant. Thus, prenatal genetic testing may be an area for enhanced education to allow for earlier diagnosis and more timely precision care in patients diagnosed with critical CHD prenatally. 
| Dual diagnoses
| Incidental diagnoses
Limitations
